Literature DB >> 18596284

More on melanoma with transdifferentiation.

Michael A Panzara, Carmen Bozic, Alfred W Sandrock.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18596284     DOI： 10.1056/NEJMc086089

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  9 in total

1.  Natalizumab in the treatment of multiple sclerosis.

Authors:  Ozgür Yaldizli; Norman Putzki
Journal:  Ther Adv Neurol Disord       Date:  2009-03       Impact factor: 6.570

2.  Melanoma complicating treatment with natalizumab (tysabri) for multiple sclerosis.

Authors:  Azza Ismail; Julie Kemp; Basil Sharrack
Journal:  J Neurol       Date:  2009-07-16       Impact factor: 4.849

3.  Association of melanoma and natalizumab therapy in the Italian MS population: a second case report.

Authors:  A Laroni; M Bedognetti; A Uccelli; E Capello; G L Mancardi
Journal:  Neurol Sci       Date:  2010-11-05       Impact factor: 3.307

4.  Cancer and multiple sclerosis in the era of disease-modifying treatments.

Authors:  Christine Lebrun; Patrick Vermersch; David Brassat; Gilles Defer; Lucien Rumbach; Pierre Clavelou; Marc Debouverie; Jérôme de Seze; Sandrine Wiertlevsky; Olivier Heinzlef; Ayman Tourbah; Agnes Fromont; Marc Frenay
Journal:  J Neurol       Date:  2011-02-04       Impact factor: 4.849

Review 5.  Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis.

Authors:  Henrik Gensicke; David Leppert; Özgür Yaldizli; Raija L P Lindberg; Matthias Mehling; Ludwig Kappos; Jens Kuhle
Journal:  CNS Drugs       Date:  2012-01-01       Impact factor: 5.749

Review 6.  Bridging, switching or drug holidays - how to treat a patient who stops natalizumab?

Authors:  Joachim Havla; Ingo Kleiter; Tania Kümpfel
Journal:  Ther Clin Risk Manag       Date:  2013-10-03       Impact factor: 2.423

Review 7.  Development of oral immunomodulatory agents in the management of multiple sclerosis.

Authors:  Richard Nicholas; Paolo Giannetti; Ali Alsanousi; Tim Friede; Paolo A Muraro
Journal:  Drug Des Devel Ther       Date:  2011-05-10       Impact factor: 4.162

Review 8.  Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities.

Authors:  Justin M Honce; Lidia Nagae; Eric Nyberg
Journal:  Mult Scler Int       Date:  2015-09-21

Review 9.  Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis.

Authors:  Paul L McCormack
Journal:  Drugs       Date:  2013-09       Impact factor: 11.431
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.